glp-1 ibd 🚨 RA use in is rising fast In this 14-month repeated survey of patients with IBD: 📈 GLP-1 RA use rose 5-fold ⚖️ Median BMI fell from 35.3 → 31.2 Tolerability of GLP-1 RAs in

Meanwhile, as shown in Figure 2C, there was no significant difference in cecal intubation time among the three groups ( p = 0.672)

Focus on taking in protein first, even if that means having to drink your calories with a meal replacement shake (just be mindful of the sugar content in your shakes)

Evidence is lacking on the effects of the many dietary supplements on offer, such as vitamins, flavonoids, plant extracts, and trace elements

The Research History in One Sentence Ipamorelin has established receptor pharmacology and limited human research, but the controlled proof of concept study did not demonstrate significant differences in its main efficacy analyses and did not lead to an identified UK authorisation